Furthermore, up to 7% of mesothelioma patients may harbor germline variants in DNA repair complex genes such as BRCA1, BRIP1, CHEK2, SLX4, FLCN and BAP1 [45] and these mutations may predispose one to the therapeutic effects of PARP inhibitors. The gene discussed is BAP1; the disease is mesothelioma.